JPWO2023283615A5 - - Google Patents
Info
- Publication number
- JPWO2023283615A5 JPWO2023283615A5 JP2024500476A JP2024500476A JPWO2023283615A5 JP WO2023283615 A5 JPWO2023283615 A5 JP WO2023283615A5 JP 2024500476 A JP2024500476 A JP 2024500476A JP 2024500476 A JP2024500476 A JP 2024500476A JP WO2023283615 A5 JPWO2023283615 A5 JP WO2023283615A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- oligonucleotide
- complex
- optionally
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163220108P | 2021-07-09 | 2021-07-09 | |
| US63/220,108 | 2021-07-09 | ||
| PCT/US2022/073529 WO2023283615A1 (en) | 2021-07-09 | 2022-07-08 | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024527362A JP2024527362A (ja) | 2024-07-24 |
| JP2024527362A5 JP2024527362A5 (https=) | 2025-07-17 |
| JPWO2023283615A5 true JPWO2023283615A5 (https=) | 2025-07-17 |
Family
ID=84802089
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024500476A Pending JP2024527362A (ja) | 2021-07-09 | 2022-07-08 | 筋標的化複合体およびジストロフィノパチーを処置するためのその使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240318177A1 (https=) |
| EP (1) | EP4366783A4 (https=) |
| JP (1) | JP2024527362A (https=) |
| KR (1) | KR20240035826A (https=) |
| CN (1) | CN118591391A (https=) |
| AU (1) | AU2022306692A1 (https=) |
| CA (1) | CA3226307A1 (https=) |
| IL (1) | IL309935A (https=) |
| MX (1) | MX2024000493A (https=) |
| WO (1) | WO2023283615A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019513371A (ja) | 2016-04-01 | 2019-05-30 | アビディティー バイオサイエンシーズ エルエルシー | 核酸ポリペプチド組成物とその使用 |
| US12370264B1 (en) | 2018-08-02 | 2025-07-29 | Dyne Therapeutics, Inc. | Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject |
| US11911484B2 (en) | 2018-08-02 | 2024-02-27 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| EP3829595A4 (en) | 2018-08-02 | 2022-08-24 | Dyne Therapeutics, Inc. | MUSCLE-DIRECTED COMPLEXES AND USES THEREOF IN THE TREATMENT OF DYSTROPHINOPATHIES |
| US12097263B2 (en) | 2018-08-02 | 2024-09-24 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US20220193250A1 (en) | 2018-08-02 | 2022-06-23 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US12497615B2 (en) | 2019-04-25 | 2025-12-16 | Avidity Biosciences, Inc. | Nucleic acid compositions and methods of multi-exon skipping |
| US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| IL309936A (en) | 2021-07-09 | 2024-03-01 | Dyne Therapeutics Inc | Muscle targeting complexes and formulations for the treatment of dystrophinopathy |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11672872B2 (en) | 2021-07-09 | 2023-06-13 | Dyne Therapeutics, Inc. | Anti-transferrin receptor antibody and uses thereof |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US11633498B2 (en) | 2021-07-09 | 2023-04-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US12071621B2 (en) | 2022-04-05 | 2024-08-27 | Avidity Biosciences, Inc. | Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping |
| US20250339553A1 (en) | 2022-04-15 | 2025-11-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and formulations for treating myotonic dystrophy |
| AU2024299328A1 (en) | 2023-07-21 | 2026-01-22 | Marrow Therapeutics, Inc. | Hematopoietic cell targeting conjugates and related methods |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9722131D0 (en) * | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| AU2008317566B2 (en) * | 2007-10-26 | 2014-05-01 | Academisch Ziekenhuis Leiden | Means and methods for counteracting muscle disorders |
| CA3044531A1 (en) * | 2016-11-28 | 2018-05-31 | The Board Of Regents Of The University Of Texas System | Prevention of muscular dystrophy by crispr/cpf1-mediated gene editing |
| EP3829595A4 (en) * | 2018-08-02 | 2022-08-24 | Dyne Therapeutics, Inc. | MUSCLE-DIRECTED COMPLEXES AND USES THEREOF IN THE TREATMENT OF DYSTROPHINOPATHIES |
| US12497615B2 (en) * | 2019-04-25 | 2025-12-16 | Avidity Biosciences, Inc. | Nucleic acid compositions and methods of multi-exon skipping |
| US12479922B2 (en) * | 2019-10-10 | 2025-11-25 | Cytolynx Therapeutics Hong Kong Limited | Humanized monoclonal antibody targeting BCMA and having human monkey cross-reactivity |
| KR20230044242A (ko) * | 2020-07-23 | 2023-04-03 | 다인 세라퓨틱스, 인크. | 근육 표적화 복합체 및 디스트로핀병증을 치료하기 위한 그의 용도 |
-
2022
- 2022-07-08 EP EP22838587.8A patent/EP4366783A4/en active Pending
- 2022-07-08 US US18/577,378 patent/US20240318177A1/en active Pending
- 2022-07-08 AU AU2022306692A patent/AU2022306692A1/en active Pending
- 2022-07-08 WO PCT/US2022/073529 patent/WO2023283615A1/en not_active Ceased
- 2022-07-08 CA CA3226307A patent/CA3226307A1/en active Pending
- 2022-07-08 KR KR1020247004340A patent/KR20240035826A/ko active Pending
- 2022-07-08 IL IL309935A patent/IL309935A/en unknown
- 2022-07-08 MX MX2024000493A patent/MX2024000493A/es unknown
- 2022-07-08 CN CN202280060812.8A patent/CN118591391A/zh active Pending
- 2022-07-08 JP JP2024500476A patent/JP2024527362A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL309935A (en) | Muscle targeting complexes and uses thereof for treating dystrophinopathies | |
| IL309937A (en) | Muscle targeting complexes and uses thereof for treating dystrophinopathies | |
| IL309911A (en) | Muscle targeting complexes and uses thereof for treating dystrophinopathies | |
| IL309909A (en) | Muscle targeting complexes and uses thereof for treating dystrophinopathies | |
| IL309912A (en) | Muscle targeting complexes and their uses for the treatment of dystrophinopathy | |
| JPWO2023283615A5 (https=) | ||
| JPWO2023283624A5 (https=) | ||
| US20240325558A1 (en) | Muscle targeting complexes and uses thereof for treating myotonic dystrophy | |
| JPWO2022020107A5 (https=) | ||
| JPWO2023283613A5 (https=) | ||
| JPWO2021142307A5 (https=) | ||
| JPWO2023283614A5 (https=) | ||
| US20240117356A1 (en) | Muscle targeting complexes and uses thereof for treating myotonic dystrophy | |
| JPWO2023283619A5 (https=) | ||
| JP2024160045A5 (https=) | ||
| US20250099603A9 (en) | Muscle targeting complexes and uses thereof for treating friedreich's ataxia | |
| KR20240035825A (ko) | 디스트로핀병증을 치료하기 위한 근육 표적화 복합체 및 제제 | |
| JP2024540199A (ja) | ジストロフィノパチーを処置するための筋標的化複合体 | |
| IL315944A (en) | Muscle targeting complexes and uses thereof for treating myotonic dystrophy | |
| JP2026503873A (ja) | Ｄｍｄ遺伝子のエクソン４５をスキップするための筋肉標的化複合体およびその使用 | |
| JPWO2020028832A5 (https=) | ||
| IL316206A (en) | Dosage of muscle targeting complexes for the treatment of myotonic dystrophy | |
| JPWO2021142313A5 (https=) | ||
| JPWO2021142234A5 (https=) | ||
| JPWO2021142227A5 (https=) |